Celltrion Signs Contract for Pharmaceutical Contract Development and Manufacturing Worth 111.2 Billion KRW
[Asia Economy Reporter Kwon Jaehee] Celltrion announced on the 19th that it has signed a contract with TEVA Pharmaceuticals International GmbH for the contract development and manufacturing of the active pharmaceutical ingredient of the migraine treatment Ajovy® worth 111.2 billion KRW. This amount corresponds to 5.8% of the sales revenue in 2021.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Seventysomething Woman Dies After Being Hit by Private Ambulance Running Red Light with Siren On
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
The contract period is from August 19, 2022, to March 31, 2024.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
